| Ytd | -17.24% | |
| 1y | -21.95% |
| Open | 4.62 | Prev Close | 4.64 | Low | 4.52 | High | 4.84 | Mkt Cap | 112.59M |
| Vol | 0.00 | Avg Vol | 211.81K | EPS | -1.12 | P/E | -4.29 | Forward P/E | -4.25 |
| Beta | 0.60 | Short Ratio | 1.53 | Inst. Own | 19.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.84 | 200-d Avg | 5.00 | 1yr Est | 15.50 |
COYA News
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to th
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONT
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus ra
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results befo
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimi
Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale a
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinic
During Friday, 24 stocks hit new 52-week lows.